$206 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 32 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 128.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $20,949,000 | +70.7% | 2,673,718 | +64.5% | 10.15% | +234.2% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $16,653,000 | +9.3% | 1,704,500 | +28.9% | 8.07% | +113.9% |
| BLU | Buy | BELLUS HEALTH INC NEW | $10,679,000 | +73.5% | 1,070,000 | +32.1% | 5.18% | +239.4% |
| VSTM | New | VERASTEM INC | $9,496,000 | – | 3,720,930 | +100.0% | 4.60% | – |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $7,117,000 | +127.4% | 63,200 | +180.9% | 3.45% | +345.2% |
| BTAI | New | BIOXCEL THERAPEUTICS INC | $7,040,000 | – | 315,000 | +100.0% | 3.41% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $6,051,000 | – | 1,384,600 | +100.0% | 2.93% | – |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $5,613,000 | -2.2% | 209,500 | +11.7% | 2.72% | +91.4% |
| LSACU | New | LIFESCI ACQUISITION CORPunit 03/31/2025 | $5,599,000 | – | 560,000 | +100.0% | 2.71% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $4,824,000 | – | 827,500 | +100.0% | 2.34% | – |
| RLMD | New | RELMADA THERAPEUTICS INC | $3,102,000 | – | 90,950 | +100.0% | 1.50% | – |
| QURE | Buy | UNIQURE NV | $2,515,000 | +40.3% | 53,000 | +112.0% | 1.22% | +174.5% |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $2,107,000 | – | 1,038,000 | +100.0% | 1.02% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $1,993,000 | – | 39,000 | +100.0% | 0.97% | – |
| ZFGN | Buy | ZAFGEN INC | $1,067,000 | -3.9% | 1,386,000 | +38.6% | 0.52% | +88.0% |
| ABUS | New | ARBUTUS BIOPHARMA CORP | $273,000 | – | 269,907 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.